VCU Secures NIH Grant for Heart Failure Clinical Trial

Virginia Commonwealth University and the University of Virginia received a $3.8 million NIH grant for a Phase 2 clinical trial. This study will investigate an anti-inflammatory medication, an interleukin-1 blocker, for heart failure patients. Enrolling 80 participants in early 2027, the research aims to determine if this therapy warrants a larger-scale trial, potentially advancing new treatment options for heart failure.